Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Develops Blood-Based RNAi Monitoring Approach

Premium

Alnylam Pharmaceuticals this week announced that it has developed a new method for monitoring RNAi activity in blood samples.

According to the company, the approach allows for the “quantitative measurement of tissue-specific mRNA silencing from biological fluids including blood and cerebrospinal fluid.” Alnylam said it expects to “enable” the use of the technology by academics and out-license it for industry applications.

A license has already been granted to Isis Pharmaceuticals.

The method “enables routine and frequent measurement of tissue-specific target gene silencing, without the need for invasive tissue biopsies,” Alnylam Vice President of Research Rachel Meyers said in a statement.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.